Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts)

Diabetes, Obesity and Metabolism

Volumn 11, Issue 1, 2009, Pages 27-32

  Raskin, Phili ^a   Matfin, G ^b   Schwartz, S L ^c   Chaykin, L ^d   Chu, P L ^b   Braceras, R ^b   Wynne, A ^e  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b NOVO NORDISK INC   (United States)

^c Diabetes and Glandular Disease Clinic   (United States)

^d Aventura Hospital and Medical Center ^*  (United States)

^e Diabetes and Endocrinology Center ^*  (United States)

Author keywords

Initiation of therapy; NovoLog Mix 70 30; NovoMix 30; Oral antidiabetic; Thiazolidinedione; Treat to target

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MALE; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; SELF MONITORING; SIDE EFFECT; WEIGHT GAIN;

EID: 58149177356     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00796.x     Document Type: Article

References (17)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972.
4. Koro CE, Bowlin SJ, Bourgeois N et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: A preliminary report. Diabetes Care 2004; 27: 17-20.
5. Saaddine JB, Cadwell B, Gregg EB et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 2006; 144: 465-474.
6. Harris M, Flegal KM, Eastman RC, Cowie CC, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999; 22: 403-408.
7. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-342.
8. Hermansen K, Colombo M, Storgaard H, Ostergaard A, Kølendorf K, Madsbad S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002; 25: 883-888.
9. McSorley PT, Bell PM, Jacobsen LV, Kristensen A, Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: A double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002; 24: 530-539.
10. Declaration of Helsinki. Recommendations guiding medical physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-926.
11. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
12. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2003; 26(Suppl. 1): S28-S32.
13. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265.
14. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: A 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26: 2034-2044.
15. Garber AJ, Wahlen J, Wahl T et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006; 8: 58-66.
16. Prescribing Information for Pioglitazone (Actos). Deerfield: Takeda Pharmaceuticals America, Inc., 2006.
17. Rosenstock J, Einhorn D, Hershon K et al. Efficacy and safety of pioglitazone in type 2 diabetes: A randomized, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56: 251-257.